Inhibitors of FTO, such as CS1 and CS2, have demonstrated the ability to sensitize tumor cells to T-cell-mediated cytotoxicity by downregulating immune checkpoint molecules like LILRB4, a member of the leukocyte immunoglobulin-like receptor subfamily B, which has been implicated in immune evasion in AML [104,105,106]. This evidence concerns the gene LILRB4 and acute myeloid leukemia.